**RARS1-related hypomyelinating leukodystrophy: Expanding the spectrum**

Marisa I. Mendes1,*, Lydia M. C. Green2,*, Enrico Bertini3, Davide Tonduti4, Chiara Aiello3, Desiree Smith1, Ettore Salsano5, Shanice Beerepoot6,7, Jozef Hertecant8, Sarah von Spiczak9,10, John H. Livingston11,12, Lisa Emrick12,13, Jamie Fraser14, Laura Russell15, Genevieve Bernard16, Stefania Magri19, Daniela Di Bella19, Franco Taroni19, Mary K. Koenig20, Isabella Moroni21, Gerarda Cappuccio22,23, Nicola Brunetti-Pierri22,23, Jullie Rhee24, Bryce A. Mendelsohn25, Ingo Helbig26,27, Katherine Helbig28, Hiltrud Muhle10, Omar Ismayl29, Adeline L. Vanderver25, Gajja S. Salomons1, Marjo S. van der Knaap6,7,30 & Nicole I. Wolf6,7

1Metabolic Unit, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
2Department of Paediatric Neurology, Leeds Teaching Hospitals Trust, Leeds, United Kingdom
3Unit of Neuromuscular and Neurodegenerative Disease, Bambino Gesù Children’s Hospital IRCCS, Rome, Italy
4Child Neurology Unit, V. Buzzi Children’s Hospital, Milano, Italy
5Unit of Rare Neurodegenerative and Neurometabolic Disease, Fondazione IRCCS Istituto Neurologico “C.Besta”, Milano, Italy
6Department of Pediatric Neurology, Emma Children’s Hospital, Amsterdam UMC, Amsterdam, The Netherlands
7Amsterdam Neuroscience, Vrije Universiteit, Amsterdam, The Netherlands
8Paediatric Genetic and Metabolic Service, Tawam Hospital, Al Ain, United Arab Emirates
9DRK-Northern German Epilepsy Centre for Children and Adolescents, Schwentinental-Raisdorf, Germany
10Department of Pediatrics II, University Medical Center Schleswig-Holstein, Christian-Albrecht University, Kiel, Germany
11Leeds Institute of Medical Research, University of Leeds, Leeds, UK
12Division of Neurology and Developmental Neurosciences, Baylor College of Medicine, Houston, Texas
13Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
14Division of Genetics and Metabolism, Rare Disease Institute, Children’s National Health System, Washington, District of Columbia
15Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, Canada
16Departments of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montreal, Canada
17Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montreal, Canada
18MyelinGene Laboratory, Research Institutes of the McGill University Health Centre, Montreal, Canada
19Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
20Department of Paediatrics, University of Texas McGovern Medical School, Houston, Texas
21Department of Paediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
22Department of Translational Medicine, Federico II University, Pozzuoli, Naples, Italy
23Telethon Institute of Genetics and Medicine, Pozzuoli, Naples, Italy
24Department of Child Neurology, Children’s National Health Systems, Washington, District of Columbia
25Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, California
26Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
27Division of Pediatric Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania
28Division of Neurology, Roberts Center for Pediatric Research, Philadelphia, Pennsylvania
29Department of Child Neurology, Sheikh Khalifa Medical City, Abu Dhabi, United Arab Emirates
30Department of Functional Genomics, Centre for Neurogenomics and Cognitive Research, VU University, Amsterdam, The Netherlands

**Correspondence**

Nicole I. Wolf, Department of Child Neurology, Amsterdam University Medical Centre, Location VUMc, De Boelelaan 1118, 1081 HV Amsterdam, The Netherlands.
Tel: +31-20-4444879; Fax: +31-20-4440855; E-mail: n.wolf@amsterdamumc.nl

**Funding Information**

Dr. Bernard has received the New Investigator Salary Award from the Canadian Institutes of Health Research.

© 2019 The Authors. *Annals of Clinical and Translational Neurology* published by Wiley Periodicals, Inc on behalf of American Neurological Association.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Institutes of Health Research (2017-2022). Dr. Green’s stay at the Centre for Childhood White Matter Disease, Amsterdam was funded by the National Institute of Health Research. Dr. Bertini has received funding from the Italian Ministry of Health (Ricerca Corrente and Ricerca Finalizzata grant GR-2016-0236337 and RF-2016-02361285, respectively. Drs. Cappuccio and Brunetti-Pierri received grant GSP15001 from the Telethon Foundation Telethon Undiagnosed Diseases Program.

Received: 27 August 2019; Revised: 9 November 2019; Accepted: 14 November 2019

Annals of Clinical and Translational Neurology 2020; 7(1): 83–93
doi: 10.1002/acn3.50960

*These authors contributed equally to this work.

Introduction

Hypomyelinating leukodystrophies are a heterogeneous group of genetic white matter disorders resulting from a significant and permanent deficit in myelin deposition within the central nervous system. Since the description of the first hypomyelinating leukodystrophy, Pelizaeus-Merzbacher disease (PMD) in 1885 and its pathology in 1910, numerous disorders characterized by hypomyelination have been identified through MRI pattern recognition analysis, genetic linkage and more recently next generation sequencing techniques. This combined approach has resulted in the identification of a number of genetic variants associated with hypomyelination, many of which are individually so rare that the resultant phenotypes are yet to be fully defined.

Variants in the RARS1 gene have been previously reported in 10 patients with a hypomyelinating leukodystrophy (MIM 616140), each presenting with nystagmus, ataxia and spasticity resembling PMD. RARS1 encodes cytoplasmic arginyl-tRNA synthetase (ArgRS), a monomeric enzyme in class 1 of the aminoa-cyl-tRNA synthetase (aaRS) family, essential for protein synthesis. ArgRS exists in a short and a long isoform, both translated from the same transcript, with the short isoform being translated from an alternative start codon causing the absence of the N-terminal 72 amino acids in the short isoform. This isoform is found free in the cytosol, whereas the long isoform is found in a subcomplex together with aaRS complex-interacting multifunctional protein 1 (AIMP1) and glutaminyl-tRNA synthetase (GlnRS), within a larger multisynthetase complex of nine tRNA synthetases and three accessory proteins in total.

Although the exact mechanism(s) underlying pathogenicity of RARS1 variants remain(s) unknown, there is increasing evidence in other tRNA synthetase disorders that aminoacylation errors contribute to cellular dysfunction. However, whether aminoacylation is impaired in RARS1-related hypomyelination, has not yet been demonstrated yet. In this paper we report 20 patients with hypomyelination and RARS1 variants, 16 new and four reported previously, expanding the clinical and neuroradiological presentation. In addition, ArgRS activity was analyzed for four patients, confirming the impact of RARS1 variants on aminoacylation.

Patients and Methods

Patients and data collection

We included 20 patients from 15 unrelated families and multinational institutes. Four patients (P1–4) were published previously. RARS1 variants were identified locally by clinical next generation sequencing techniques (either WES or WES with a filter for leukodystrophy genes,
which included RARS1, a known disease gene) following local procedures. After the identification of biallelic RARS1 mutations by the referring centers, the Centre for Childhood White Matter Diseases, Amsterdam was contacted by the treating clinician, and clinical and radiological data were retrospectively collected there. These data were evaluated by LG and NW at the Centre for Childhood White Matter Diseases, Amsterdam. The study was approved by the Institutional Review Board of VU University Medical Centre and the participating institutes. All patients/parents gave appropriate informed consent.

Enzyme assay

Aminoacylation was assessed by measuring ArgRS activity in cultured fibroblasts of 4 patients. Fibroblast lysates (cytosolic fraction) were incubated in triplicate at 37°C for 10 minutes in a reaction buffer containing 50 mmol/L Tris buffer pH 7.5, 12 mmol/L MgCl$_2$, 25 mmol/L KCl, 1 mg/mL bovine serum albumin, 0.5 mmol/L spermine, 1 mmol/L ATP, 0.2 mmol/L yeast total tRNA, 1 mmol/L dithiothreitol, 0.3 mmol/L [13C$_6$]arginine, [13C]-valine and [D$_2$]-glycine. The reaction was terminated using trichloroacetic acid. After sample washing with trichloroacetic acid, ammonia was added to release the labeled amino acids from the tRNAs. [13C$_6$]-arginine, [13C]-valine and [13C$_2$, 15N]-glycine were added as internal standards and the labeled amino acids were quantified by LC-MS/MS. Intra-assay variation was <15%. Valyl-tRNA synthetase Glcyyl-tRNA synthetase activity were simultaneously detected as control enzymes.

Western blot

To confirm the presence of ArgRS protein in fibroblasts, a western blot was performed. Cell pellets were resuspended in urea lysis buffer (10 mmol/L Tris HCl, 8 mol/L urea, 100 mmol/L NaCl, pH 8.0). After DNA shearing using a 29-gauge needle, protein concentration was determined and 30 µg of total protein were separated in a 12% stain-free SDS gel (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred onto a polyvinylidene fluoride membrane (Bio-Rad, Hercules, CA) using a Trans-Blot Turbo Transfer System (Bio-Rad). Immunodetection was performed using a primary antibody (rabbit) directed at ArgRS (PAS-30145, Thermo Fisher Scientific, Waltham, MA) and a secondary anti-rabbit antibody (PO448, Dako, Glostrup, Denmark). Immune complexes were detected by enhanced chemiluminescence (Lumilight Plus), according to the manufacturer’s specifications (Roche, Indianapolis, IN). Images were acquired in a charge-coupled device imager ChemiDoc XRS (Bio-Rad) using the Image Lab software (Bio-Rad).

Results

Clinical characteristics

Detailed clinical characteristics are provided in Table S1. Eighteen of the 20 patients presented in the first year of life, 11/18 under the age of 3 months. Seven patients presented with delayed motor development, five with seizures and one with nystagmus. The other five presented with microcephaly (n = 2), irritability (n = 2) or failure to thrive (n = 1). The two patients who had their first signs after the age of 12 months presented with nystagmus and frequent falls at age 3 years and with delayed language and social development at age 2 years. Over time, 12 patients developed nystagmus, 13 spasticity, seven ataxia and 10 epilepsy. Seizures were refractory to treatment in eight of these 10 cases, the clinical picture suggesting infantile epileptic encephalopathy. At the time of reporting five patients, all with disease onset before the age of 3 months, were deceased (aged 21–42 months).

Of the surviving 15 patients, 13 had intellectual disability, ranging from mild to moderate (n = 6) to severe (n = 7). Of the six patients who achieved walking, two continued to require support at their latest follow-up (P1, aged 11 years, and P3, aged 26 years), four were independently mobile, and one became wheelchair dependent later in life. The most mildly affected patient (P10) initially presented aged 3 years with transient nystagmus and clumsiness, and did not develop concerns regarding cognition and progressive lower limb spasticity until the fourth and fifth decades.

Based on these findings, we classified clinical presentation as:

1 Severe (presenting in the first 3 months of life, and usually with refractory epilepsy),
2 Intermediate (the classic hypomyelinating phenotype resembling PMD and related disorders, with onset within the first year of life, nystagmus and spasticity, but sometimes with the ability to walk with support), and
3 Mild (with an onset around age 12 months and the ability to walk without support).

This spectrum is a continuum: for example, P4 is an example of a borderline patient between the severe and intermediate form.

Radiological findings

MRI scans were available for 17 of the 20 patients: for one patient (P6) no MRI was available, and for two patients (P13 and P19), we had only selected images. Detailed MRI findings are provided in Table S2 and Figures 1, 2. Throughout the cohort, T2-weighted images demonstrated supratentorial white matter hyperintensity with corresponding T1 hypointensity, in keeping with
Figure 1. Demonstrating the spectrum of MRI findings in selected patients with RARS1. Axial T2-weighted and sagittal T1-weighted (P19, P5, P4, P1, P20) and T2-weighted images (P17, P14), from the most to the least severely affected patient. The severely affected patients have early-onset cerebral atrophy and, in patient 5, also cerebellar atrophy, in addition to abnormal T2 hyperintense signal of the cerebral white matter, indicating myelin deficit. P19, the most severely affected patient, also has a simplified gyral pattern and a round, small cerebellum.
myelin deficit. Some patients were too young to establish a radiological diagnosis of hypomyelination, but even the youngest patients showed deficient myelination.

Nine patients demonstrated some degree of early brain atrophy; this corresponded with severe clinical presentation. P10 with a mild presentation also showed atrophy at the age of 50 years; it is unclear over how much time this had developed.

The most severely affected patient, P19, had a simplified gyral pattern in addition to hypomyelination and brain atrophy (Figs. 1, 2A and B). There was no evidence of cortical malformations in the remaining patients. One of the patients, P15, had bilateral T2-hyperintense signal in the ventrolateral part of the thalamus (Fig. 2C and D). We did not find spinal cord abnormalities in the patients we could assess this question.

**RARS1 variants**

Full details of the RARS1 variants identified within the cohort are given in Table 1 and Figure 3. Five patients were identified to have homozygous and 15 compound heterozygous variants; six variants were previously reported whilst 15 were novel. The most common variant...
| Patient   | Subtype | Genotype 1 | Genotype 2 | Age of onset | Nystagmus | Microcephaly | Highest motor milestone | Epilepsy difficulties | Feeding difficulties | Main MRI findings |
|-----------|---------|------------|------------|--------------|-----------|--------------|------------------------|----------------------|---------------------|------------------|
| Nafisinia et al. (patient 3) | Severe | c.1367C>T p.(Ser456Leu) | c.1846_1847del p.(Val616Leufs*6) | 3 months | Y         | Y             | Sitting without support | Y                    | Unknown            | Y                |
| Rezaei et al. (patient 1) | Severe | c.2T>C p.(Met17) | c.2T>C p.(Met17) | First months | Y         | Y             | Head control (lost age 7 months) | N                    | Unknown            | Y                |
| Rezaei et al. (patient 2) | Severe | c.2T>C p.(Met17) | c.2T>C p.(Met17) | First months | Y         | Y             | Head control          | Y                    | Unknown            | Y                |
| P4        | Severe | c.1A>G p.(Met17) | c.1535G>A p.(Arg512Gln) | 2 months | Y         | Y             | Rolls over            | N                    | Y                  | Y (mild)          |
| P5        | Severe | c.1316C>A p.(Ala439Asp) | c.1316C>A p.(Ala439Asp) | 3 months | Y         | Y             | Partial head control | Y                    | Y                  | Y                |
| P6        | Severe | c.1316C>A p.(Ala439Asp) | c.1316C>A p.(Ala439Asp) | Congenital | Unknown | Y             | Partial head control | Y                    | Y                  | n/a              |
| P7        | Severe | c.173T>C p.(Leu58Pro) | c.1790T>C p.(Leu597Pro) | Congenital | Y         | No milestones achieved | | Y                    | Y                  | Y (mild)           |
| P11       | Severe | c.67_70del p.(Thr23Leufs*6) | c.67_70del p.(Thr23Leufs*6) | Congenital | Y         | Y             | Partial head control | Y                    | Y                  | Y                |
| P12       | Severe | c.67_70del p.(Thr23Leufs*6) | c.67_70del p.(Thr23Leufs*6) | Congenital | Y         | Y             | Partial head control | Y                    | Y                  | Y                |
| P15       | Severe | c.2T>A p.(Met17) | c.448_456del p.(Cys150_Glu152del) | 6 weeks | N         | Y             | Partial head control | Y                    | Y                  | Y                |
| P16       | Severe | c.2T>C p.(Met17) | c.1535G>A p.(Arg512Gln) | Congenital | Y         | Rolls over, partial head control | | Y                    | Y                  | Y                |
| P17       | Severe | c.1452+1G>A p.(?) | c.1534C>T p.(Arg512Trp) | 2 months | N         | No milestones achieved | | Y                    | Y                  | Y                |
| P18       | Severe | c.1452+1G>A p.(?) | c.1534C>T p.(Arg512Trp) | Congenital | Y         | No milestones achieved | | Y                    | Y                  | Y                |
| P19       | Severe | c.3G>T p.(Met17) | c.96_97del p.(Cys32Trpfs*39) | Congenital | N         | No milestones achieved | | Y                    | Y                  | Y                |
| Ji et al. (patient 118) | Intermediate | c.5A>G p.(Asp2Gly) | c.1625+2T>G p.(?) | 3 months | Y         | Unknown (severe motor impairment) | | N                    | N                  | Y (mild)          |
| P1^1      | Intermediate | c.5A>G p.(Asp2Gly) | c.45+1G>T p.(?) | 1 year | Y         | N             | Walks with support | N                    | N                  | Y                |
| P2^1      | Intermediate | c.5A>G p.(Asp2Gly) | c.45+1G>T p.(?) | 5 months | Y         | Sits without support, crawls | | N                    | N                  | Y                |
| P3^1      | Intermediate | c.5A>G p.(Asp2Gly) | c.96_97del p.(Cys32Trpfs*39) | 10 months | Y         | N             | Walks with support | N                    | N                  | Y                |
| Patient | Subtype | Genotype 1 | Genotype 2 | Age of onset | Nystagmus | Microcephaly | Highest motor milestone | Epilepsy | Feeding difficulties | Hypomyelination | Atrophy |
|---------|---------|------------|------------|--------------|-----------|-------------|------------------------|----------|---------------------|----------------|---------|
| P8      | Intermediate | c.5A>G    | c.1874-9_1874-5del p.? | 10 months | Y | N | Sits without support | N | N | Y | Y (mild) |
| P9      | Intermediate | c.5A>G    | c.1874-9_1874-5del p.? | 10 months | Y | N | Sits without support | N | N | Y | Y (mild) |
| P13     | Intermediate | c.668G>A p.(Arg223His) | c.1568T>A p.(Met523Lys) | 9 months | N | N | Walks without support | N | Y | N | N |
| Nafisinia et al. (patient 1) | Mild | c.5A>G p.(Asp2Gly) | c.5A>G p.(Asp2Gly) | <12 months | Y | Unknown | Walks without support | N | N | Y | Y (late) |
| Nafisinia et al. (patient 2) | Mild | c.5A>G p.(Asp2Gly) | c.5A>G p.(Asp2Gly) | <12 months | Y | Unknown | Walks without support | N | N | n/a | n/a |
| P10     | Mild | c.5A>G p.(Asp2Gly) | c.5A>G p.(Asp2Gly) | 3/45 years | Transient | N | Walks without support | N | N | Y | Y (late) |
| P14     | Mild | c.5A>G p.(Asp2Gly) | c.173T>C p.(Leu58Pro) | 18 months | N | Y | Walks without support | N | N | Y | N |
| P20     | Mild | c.475C>T p.(Pro159Ser) | c.1367C>T p.(Ser456Leu) | 2 years | N | N | Walks without support | N | N | N | N |

In bold: *RARS1* variants present in more than one family. Y, yes; N, no.

1Previously published by Wolf et al (2014). Variants present in at least two unrelated families are depicted in bold.

2Transient period of clumsiness with frequent falls and rotatory nystagmus aged 3 years, followed by mild cognitive concerns not affecting daily living from early 30s, and progressive lower limb spasticity affecting walking from mid-40s.
within our cohort was c.5A>G p.(Asp2Gly), a substitution located at the very beginning of the N-terminal domain. This variant was identified in seven of the 20 patients (one homozygous, six compound heterozygous) and was also described in two other published patients in a homozygous form. All patients with this variant had an intermediate or a mild (when homozygous) phenotype.

We ascertained other recurrent variants that were present in more than one family: p.(Ser456Leu), reported previously and present in P20; p.(Leu58Pro) present in P7 and P14; p.(Cys32Thrfs*39) present in P3 and P19; and several variants that affected the start codon (in four patients). Arginine at position 512, located close to the active center (Fig. 3), was affected in three unrelated families, all presenting with severe disease. Furthermore, other variants affecting amino acids in close proximity to the arginine binding site (in eight patients/six families) led to severe phenotypes (Fig. 3), with the exception of p.(Arg223His). The p.(Leu58Pro) variant, located close to the interface with GlnRS (Fig. 3), was combined in one family with p.(Asp2Gly) resulting in a mild phenotype, in another family with p.(Leu597Pro) resulting in a severe phenotype.

Several variants presumably affected translation of the full-length protein. For example, in several families the start codon was affected, resulting in (almost) absent translation of the long isoform (as demonstrated in P4, Fig. 3). These variants were also associated with a severe phenotype.

Enzyme activity and isoform translation

ArgRS activity was significantly decreased in fibroblasts of P1, P3, and P5 compared to controls (Fig. 3A). P5, with
a severe phenotype, had the lowest enzyme activity of the three patients. In contrast, P4 showed ArgRS activity in the range of the control, despite having a severe clinical phenotype. Compared to controls, P1 and P3 showed a faint band of the short ArgRS isoform; for P4, the main isoform found was the short one, although a faint band of the long ArgRS isoform was present as well (Fig. 3B).

**Discussion**

This study demonstrates the impact of biallelic RARS1 variants on neurodevelopment and confirms them as a cause of hypomyelinating leukodystrophy, similar to the hypomyelination seen in patients with variants in EPRS1 and DARS1, also coding for tRNA synthetases which are part of the multisynthetase complex.\(^{14-16}\) Besides hypomyelination, single patients with RARS1 variants share neuroradiological abnormalities with EPRS1 patients (ventrolateral thalamus involvement)\(^{14}\) and DARS1 patients (spinal cord involvement)\(^{15,16}\) although the latter, described so far in one RARS1 patient\(^ {17,}\), is not present in this cohort. We also confirm that the aminoacylating function of ArgRS is impaired, with the most pronounced reduction in a severely affected patient.

The study also sheds new light on the disease spectrum associated with RARS1 variants. Beyond presenting as a typical hypomyelinating leukodystrophy, a substantial number of patients with RARS1 variants present with early epileptic encephalopathy, the most severely affected patient also displays a cortical folding abnormality. On the other end of the spectrum, patients have mild disease, even without significant myelin deficit, again reminiscent of patients with DARS1 variants and late onset disease.\(^{15,}\)

Interestingly, patients with the severe phenotype resemble early-onset grey matter disorders rather than primary leukodystrophies: they have severe epilepsy and early-onset (severe) cerebral atrophy, both hallmarks of neuronal disorders. Patients with variants in QARS1, encoding GlnRS which closely interrelates with ArgRS within the multisynthetase complex, present with similar clinical signs.\(^ {18}\) One of the QARS1 variants disturbs the interaction between GlnRS and ArgRS,\(^ {18}\) and we assume this is also the case for the ArgRS Leu58Pro variant, located at the ArgRS-GlnRS interface. A similar severe presentation is seen in patients with biallelic mutations in AARS1\(^ {19}\) and VARS1\(^ {20,}\) and also mutations in AIMP1 and AIMP2, affecting two of the three scaffolding proteins of the multisynthetase complex, lead to early-onset neuronal disorders.\(^ {22,}\)

Thanks to this cohort of 20 patients, we are beginning to understand the genotype-phenotype relationship.\(^ {9}\) The most frequent RARS1 variant ascertained, c.5A>G p.(Asp2Gly), affects the second amino acid residue asparagine, which is part of the 72 amino-acid N-terminal domain and only present in the longer ArgRS isoform. It interacts with the long N-terminal helix of AIMP1 and also affixes the C-terminal core of GlnRS.\(^ {18}\) The Asp2Gly variant most likely leads to a mild or intermediate phenotype, as no patients with this variant has the severe early-infantile phenotype and all but two patients with the mildest phenotype are homozygous for this variant. In another study, this variant led to decreased levels of the longer ArgRS isoform in fibroblasts of a homozygous patient,\(^ {13}\) and also in our two patients compound heterozygous for this variant, we could observe a faint band for the shorter isoform in fibroblasts. One patient (P4) carries a mutation affecting the start codon c.1A>G in one allele, and shows mainly translation of the short cytosolic ArgRS isoform. We hypothesize that, due to this mutation, only the short and not the long isoform can be translated from the transcript of this allele, and that the observed faint band of the long isoform results from the transcript of the other allele. Interestingly, this patient has a severe phenotype but normal ArgRS activity in fibroblasts, in contrast to the other three patients with reduced ArgRS activity. Since the long and short ArgRS isoforms exhibit similar enzyme activities in vitro,\(^ {9}\) it is possible that the short isoform, the main isoform present in fibroblasts of this patient, contribute to the enzyme activity. As a consequence, normal ArgRS activity in vitro does not necessarily reflect aminoacylation in vivo, for which the long isoform is needed to form the multisynthetase complex.

The disparate clinical manifestations seen in this cohort – a severe neuronal phenotype on one hand and a typical leukodystrophy (hypomyelination) phenotype on the other – raise questions as to (1) whether the hypomyelination is a result of primary neuronal dysfunction instead of primary oligodendrocyte dysfunction; (2) whether mildly reduced ArgRS activity only affects oligodendrocytes while more severely reduced activity (also) affects neurons; and (3) whether different variants disturb different protein functions. It is postulated that the short cytosolic form of ArgRS, unaffected by some RARS1-variants, is involved in the ubiquitin-dependent N-end rule pathway of protein degradation by providing Arg-tRNA as a substrate for arginyl-tRNA transferase.\(^ {24}\) N-terminal arginylation targets certain proteins for controlled degradation, including elimination of misfolded proteins.\(^ {24}\) Defective protein homeostasis, due to impaired ubiquitination or ufmylation, is associated with several neurodegenerative disorders, including early-onset encephalopathies.\(^ {25-28}\) Therefore, defective ArgRS might hamper protein degradation in addition to affecting protein synthesis, thereby contributing to a primarily neuronal phenotype. Understanding these possible pathway(s) to disease manifestations is essential before embarking on approaches to treatment.
Acknowledgments

The authors are grateful to patients and families. Dr. Bernard has received the New Investigator Salary Award from the Canadian Institutes of Health Research (2017-2022). Dr. Green’s stay at the Centre for Childhood White Matter Disease, Amsterdam was funded by the National Institute of Health Research. Dr. Bertini has received funding from the Italian Ministry of Health (Ricerca Corrente and Ricerca Finalizzata grant GR-2013-023582). Drs. Magri and Taroni are funded by Italian Ministry of Health grants GR-2016-02363337 and RF-2016-02361285, respectively. Drs. Cappuccio and Brunetti-Pierri received grant GSP15001 from the Telethon Foundation. The following authors are members of the European Reference Network for Rare Neurological Disorders (ERN-RND), project ID 739510: Dr. Bertini, Dr. Aiello, Dr. Salsano, Dr. Magri, Dr. Di Bella, Dr. Taroni, Dr. Moroni, prof. Dr. van der Knaap and Dr. Wolf.

Conflict of Interest

There are no conflicts of interest directly related to this work.

References

1. Pouwels PJ, Vanderver A, Bernard G, et al. Hypomyelinating leukodystrophies: translational research progress and prospects. Ann Neurol 2014;76:5–9.
2. Pelizaeus F. Ueber eine eigenthümliche Form spastischer Lähmung mit Cerebralscheinungen auf hereditärer Grundlage. Arch Psychiatr Nervenkr 1885;16:698–710.
3. Merzbacher L. Eine eigenartige familiär-hereditäre Erkrankungsform (Aplasia axialis extracorticalis congenita). Zeitschr Ges Neurol Psychiatr 1910;1:131–134.
4. Steenweg ME, Vanderver A, Blaser S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 2010;133:2971–2982.
5. Kevelam S, Steenweg M, Srivastava S, et al. Update on leukodystrophies: a historical perspective and adapted definition. Neuropediatrics 2016;47:349–354.
6. van der Knaap MS, Schiffmann R, Mochel F, Wolf NI. Diagnosis, prognosis, and treatment of leukodystrophies. Lancet Neurol 2019;18:962–972.
7. Simons C, Dyment D, Bent SJ, et al. A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy. Brain 2017;140:3105–3111.
8. Hyeon D, Kim J, Ahn T, et al. Evolution of the multi-tRNA synthetase complex and its role in cancer. J Biol Chem 2019;294:5340–5351.
9. Zheng Y-G, Wei H, Ling C, et al. Two forms of human cytoplasmic arginyl-tRNA synthetase produced from two translation initiations by a single mRNA. Biochemistry 2006;45:1338–1344.
10. Abbott JA, Franchlyn CS, Robey-Bond SM. Transfer RNA and human disease. Front Genet 2014;5:158.
11. Yao P, Fox PL. Aminoacyl-tRNA synthetases in medicine and disease. EMBO Mol Med 2013;5:332–343.
12. Wolf NI, Salomons GS, Rodenburg RJ, et al. Mutations in RARS cause hypomyelination. Ann Neurol 2014;76:134–139.
13. Nafissina M, Sobreira N, Riley L, et al. Mutations in RARS cause a hypomyelination disorder akin to Pelizaeus-Merzbacher disease. Eur J Hum Genet 2017;25:1134–1141.
14. Mendes MI, Salazar M, Guerrero K, et al. Bi-allelic mutations in EPRS, encoding the glutamyl-prolyl-aminoacyl-tRNA synthetase, cause a hypomyelinating leukodystrophy. Am J Hum Genet 2018;102:676–684.
15. Wolf NI, Toro C, Kister I, et al. DARS-associated leukoencephalopathy can mimic a steroid-responsive neuroinflammatory disorder. Neurology 2015;84:226–230.
16. Taft RJ, Vanderver A, Leventer RJ, et al. Mutations in DARS cause hypomyelination with brain stem and spinal cord involvement and leg spasticity. Am J Hum Genet 2013;92:774–780.
17. Rezaei Z, Hosseinpoor S, Ashrafi M, et al. Hypomyelinating leukodystrophy with spinal cord involvement caused by a novel variant in RARS : report of two unrelated patients. Neuropediatrics 2019;50:130–134.
18. Zhang X, Ling J, Barcia G, et al. Mutations in QARS, encoding glutaminyl-tRNA synthetase, cause progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures. Am J Hum Genet 2014;94:547–558.
19. Simons C, Griffin LB, Helman G, et al. Loss-of-function alanyl-tRNA synthetase mutations cause an autosomal-recessive early-onset epilepticencephalopathy with persistent myelination defect. Am J Hum Genet 2015;96:675–681.
20. Friedman J, Smith DE, Issa MY, et al. Biallelic mutations in valyl-tRNA synthetase gene VARS cause hypomyelination. Ann Neurol 2014;76:134.
21. Siekierska A, Stamberger H, Deconinck T, et al. Biallelic mutations in AIMP2, encoding the glutamyl-prolyl-arginyl-tRNA synthetase, cause hypomyelination and disease. EMBO Mol Med 2013;5:332–343.
22. Feinstein M, Markus B, Noyman I, et al. Pelizaeus-Merzbacher disease. Eur J Hum Genet 2017;25:1134–1141.
23. Shukla A, Bhowmik A, Hebbar M, et al. Homozygosity for a nonsense variant in AIMP2 is associated with a progressive neurodevelopmental disorder with microcephaly, seizures, and spastic quadriaparesis. J Hum Genet 2018;63:19–25.
24. Varshavsky A. The N-end rule pathway and regulation by proteolysis. Protein Sci 2011;20:1298–1305.
25. Nahorski MS, Maddirevula S, Ishimura R, et al. Biallelic UFM1 and UFC1 mutations expand the essential role of ufmylation in brain development. Brain 2018;141:1934–1945.

26. Hamilton EM, Bertini E, Kalaydjieva L, et al. UFM1 founder mutation in the Roma population causes recessive variant of H-ABC. Neurology 2017;89:1821–1828.

27. Colin E, Daniel J, Ziegler A, et al. Biallelic variants in UBA5 reveal that disruption of the UFM1 cascade can result in early-onset encephalopathy. Am J Hum Genet 2016;99:695–703.

28. Muona M, Ishimura R, Laari A, et al. Biallelic variants in UBA5 link dysfunctional UFM1 ubiquitin-like modifier pathway to severe infantile-onset encephalopathy. Am J Hum Genet 2016;99:683–694.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Clinical features of the 20 patients with RARS1 variants.
Table S2. MRI features.